BR100 Decreased By (-0.22%)
BR30 Decreased By (-0.17%)
KSE100 Decreased By (-0.19%)
KSE30 Decreased By (-0.24%)
AGHA 7.79 Decreased By ▼ -0.02 (-0.26%)
BECO 5.19 Decreased By ▼ -0.02 (-0.38%)
BML 57.75 Increased By ▲ 0.25 (0.43%)
BOP 34.09 Increased By ▲ 0.06 (0.18%)
CNERGY 9.90 Decreased By ▼ -0.06 (-0.6%)
CSIL 5.35 Increased By ▲ 0.04 (0.75%)
FCCL 54.60 Decreased By ▼ -0.10 (-0.18%)
FFL 16.71 Increased By ▲ 0.02 (0.12%)
FNEL 1.25 Increased By ▲ 0.02 (1.63%)
KEL 7.33 Decreased By ▼ -0.07 (-0.95%)
KOSM 5.75 Decreased By ▼ -0.02 (-0.35%)
LOTCHEM 29.19 Decreased By ▼ -0.13 (-0.44%)
MLCF 93.50 Decreased By ▼ -0.86 (-0.91%)
NBP 202.84 Decreased By ▼ -0.21 (-0.1%)
NCPL 56.50 Decreased By ▼ -0.50 (-0.88%)
NPL 67.84 Increased By ▲ 0.14 (0.21%)
OGDC 316.20 Increased By ▲ 0.36 (0.11%)
PACE 10.65 Increased By ▲ 0.01 (0.09%)
PAEL 43.00 Decreased By ▼ -0.20 (-0.46%)
PIBTL 16.70 Decreased By ▼ -0.04 (-0.24%)
PPL 218.75 Decreased By ▼ -1.03 (-0.47%)
PRL 49.45 Increased By ▲ 0.26 (0.53%)
PTC 70.61 Increased By ▲ 0.08 (0.11%)
SSGC 27.90 Decreased By ▼ -0.35 (-1.24%)
TBL 9.75 Decreased By ▼ -0.11 (-1.12%)
TELE 8.79 No Change ▼ 0.00 (0%)
TPL 18.20 Decreased By ▼ -0.04 (-0.22%)
TPLP 13.38 Increased By ▲ 0.11 (0.83%)
TREET 22.52 Decreased By ▼ -0.20 (-0.88%)
TRG 60.34 Increased By ▲ 0.20 (0.33%)
Markets

European stocks end lower on virus, policy jitters

  • German consumer morale darkens: GfK
  • Travel stocks fall on virus woes
  • Swedish Orphan Biovitrum tops STOXX 600
Published Updated
By

European shares ended lower on Thursday after data showed faltering German consumer morale amid rising COVID-19 cases, while investors fretted over US monetary policy ahead of the Jackson Hole symposium.

The pan-European STOXX 600 index fell 0.3%, with mining and travel & leisure stocks leading losses.

The STOXX 600 had briefly deepened its losses towards the close, tracking a fall in US stocks after sentiment was rattled by a blast in Kabul.

Anticipation of the US Federal Reserve's annual Jackson Hole summit on Friday kept investors on their toes, with chair Jerome Powell's speech likely to offer hints on the central bank's plans to taper its massive stimulus programme.

"We think that those expecting clear communication about the shape and timing of the tapering of asset purchases may be disappointed," said Paolo Zanghieri, senior economist at Generali Investments. "The recent data remain strong, but momentum is receding and inflation fears have not surged."

Blast outside Kabul airport kills at least 13, including children: Taliban official

A survey showed the mood among German consumers darkened heading into September as accelerating inflation and rising COVID-19 cases made them more hesitant to buy.

Business morale in the euro zone's largest economy fell for the second month running in August, data on Wednesday showed.

"Risks are tilted to the downside over the near term," analysts at BCA Research said. "While global COVID-19 cases appear to be rolling over and (China's) Ningbo-Zhoushan port has reopened, which are both positive for supply chains, COVID-19 cases are still climbing in Germany."

European travel company Tui, airlines Wizz Air , Lufthansa and British Airways-owner IAG fell by between 0.9% and 3.8%.

Wizz Air was the worst performer on the STOXX 600, dropping 3.8%.

Germany's blue-chip DAX dropped 0.4%, marking its lowest closing level in a week, while the UK's FTSE 100 and France's CAC 40 declined by 0.4% and 0.2%, respectively.

Deutsche Bank's asset management arm DWS Group fell 13.7% on a report US authorities were investigating DWS over sustainability claims. Deutsche Bank's shares dropped 1.5%.

France's Vivendi rose 2.6% after its unit Universal Music Group said it expects further revenue growth this year and it aims to pay out dividends once it lists in Amsterdam.

French conglomerate Bouygues gained 1.1% as it raised its full-year earnings outlook.

Swedish Orphan Biovitrum was the best performer on the STOXX 600, rising 8.8% after Bloomberg reported that private equity firm Advent International is considering a bid for the pharmaceutical maker.

Comments

Comments are closed for this article.